{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"117.9","upperLimit":"173.7","value":"143.1"}]}],"title":"Anti-HPV Type 6 (n=101)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"68.1","upperLimit":"100.9","value":"82.9"}]}],"title":"Anti-HPV Type 11 (n=112)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"266.7","upperLimit":"394.7","value":"324.4"}]}],"title":"Anti-HPV Type 16 (n=128)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"49.5","upperLimit":"78.9","value":"62.5"}]}],"title":"Anti-HPV Type 18 (n=142)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"56.6","upperLimit":"84.4","value":"69.2"}]}],"title":"Anti-HPV Type 31 (n=135)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"37.0","upperLimit":"54.1","value":"44.7"}]}],"title":"Anti-HPV Type 33 (n=141)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.0","upperLimit":"25.5","value":"20.8"}]}],"title":"Anti-HPV Type 45 (n=148)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27.6","upperLimit":"41.1","value":"33.7"}]}],"title":"Anti-HPV Type 52 (n=134)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"40.9","upperLimit":"63.3","value":"50.9"}]}],"title":"Anti-HPV Type 58 (n=132)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"150"}],"units":"Participants"}],"description":"Serum antibodies to HPV types 6/11/16/18/31/33/45/52/58 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL. This outcome measure applied to Cohort 1 participants only.","dispersionType":"95% Confidence Interval","groups":[{"description":"V503 mid-dose 0.5 mL injection in a 3-dose regimen in the Base Study. A subset of participants (Cohort 1) received a fourth V503 mid-dose vaccination in the extension study.","id":"OG000","title":"Extension Study: Mid-dose V503 (Cohort 1)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All participants in Cohort 1 who received all 3 vaccinations of mid-dose V503 in the Base Study, were seronegative at Day 1 and PCR negative from Day 1 to Month 7 for the relevant HPV types, had no other violation that could interfere with evaluation of immune response, and provided post-dose 4 serum.","reportingStatus":"POSTED","timeFrame":"Month 60: predose 4 in the Extension Study (Cohort 1)","title":"Extension Study: Geometric Mean Titers to HPV Types 6/11/16/18/31/33/45/52/58 at Predose 4","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"milli Merck U/mL"}